IGC Pharma IGC Estimates

NYSE IGC
$0.28 0.00 (-0.07%)
As of: Sep 10, 2026 · 3:59 PM EDT
Analyst Estimates

IGC Pharma, Inc. Revenue Estimates

Periods 18
Next Period Q4 25
Consensus 193,484.61

Analysts expect IGC Pharma, Inc. to report revenue of 193,484.61 for Q4 25, against a range of 176,893.69 to 210,075.53. The most recent reported quarter, Q2 26, came in at 265,000.00, a 55.3% beat against the 170,660.04 consensus.

Metric Q3 23Q4 23Q1 25Q2 25Q3 25Q4 25Q1 26Q2 26Q3 26Q4 26Q1 27Q2 27Q3 27Q4 27Q1 28Q2 28Q3 28Q4 28
Reported (Actual) 204,000.00295,000.00260,000.00328,000.00191,000.00-317,000.00265,000.00-------
High Estimate 438,626.83211,430.31349,660.42366,397.35384,949.70210,075.53200,172.95180,638.3697,657.71305,476.25367,384.30292,053.35111,450.78292,413.50383,931.24
Low Estimate 386,653.17198,849.09287,545.58323,073.09345,435.14176,893.69169,150.51160,681.7290,388.05274,073.35304,116.80263,720.5596,319.68244,750.90343,912.22
Consensus Estimate 412,640.00205,139.70318,603.00344,735.22365,192.42193,484.61184,661.73170,660.0494,022.88289,774.80335,750.55277,886.95103,885.23268,582.20363,921.73
Analyst Estimates

IGC Pharma, Inc. Earnings Per Share (EPS) Estimates

Periods 18
Next Period Q3 26
Consensus -0.02

Analysts expect IGC Pharma, Inc. to report earnings per share of -0.02 for Q3 26, against a range of -0.02 to -0.02. The most recent reported quarter, Q2 26, came in at -0.03, a 50.0% miss against the -0.02 consensus.

Metric Q3 23Q4 23Q1 25Q2 25Q3 25Q4 25Q1 26Q2 26Q3 26Q4 26Q1 27Q2 27Q3 27Q4 27Q1 28Q2 28Q3 28Q4 28
Reported (Actual) -0.09-0.04-0.02-0.02-0.02-0.01-0.02-0.03--------
High Estimate -0.04-0.04-0.02-0.03-0.02-0.02-0.02-0.02-0.02-0.02-0.02-0.02-0.02-0.01-0.02-0.02
Low Estimate -0.04-0.04-0.02-0.03-0.02-0.02-0.02-0.02-0.02-0.02-0.02-0.02-0.02-0.01-0.02-0.02
Consensus Estimate -0.04-0.04-0.02-0.03-0.02-0.02-0.02-0.02-0.02-0.02-0.02-0.02-0.02-0.01-0.02-0.02